| Harrow is an ophthalmic-focused pharmaceutical company. Co. engages in the development, production, sale and distribution of prescription medications. Co. owns and operates ImprimisRx, the ophthalmology-focused pharmaceutical-compounding business, and its branded drugs are marketed under its Harrow name. In addition, Co. also has non-controlling equity positions in Surface Ophthalmics, Inc., which is focused on development and commercialization of therapeutics for ocular surface diseases; and Melt Pharmaceuticals, Inc., which is focused on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutics for human medical procedures. We show 22 historical shares outstanding datapoints in our HROW shares outstanding history coverage, used to compute HROW market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing HROW market cap history over the course of time is important for investors
interested in comparing HROW's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of HROW versus a peer is one thing; comparing
HROW market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like HROW can fluctuate over the course of history.
With this page we aim to empower investors researching HROW by allowing them to research the HROW market cap history.